GHRP-6: A Hexapeptide Growth Hormone Secretagogue with CD36 Engagement

Research summary. GHRP-6 (Growth Hormone-Releasing Peptide 6) is a synthetic hexapeptide and one of the founding members of the GHRP class developed by Bowers and colleagues at Tulane University in the 1980s. Like its sister molecule GHRP-2, it engages the growth hormone secretagogue receptor (GHS-R1a) — the receptor subsequently identified as the target of endogenous ghrelin. GHRP-6 is distinguished from other GHRPs by its more pronounced appetite-stimulating activity and its additional engagement of the scavenger receptor CD36, which underlies several of its non-pituitary effects.

Molecular profile

• Sequence: His-D-Trp-Ala-Trp-D-Phe-Lys-NH₂
• Molecular formula: C₄₆H₅₆N₁₂O₆
• Molecular weight: ~873.0 g/mol
• PubChem CID: 9919153
• CAS Number: 87616-84-0

The peptide includes two D-amino-acid residues (D-Trp and D-Phe) for protease resistance and a C-terminal amide that contributes to receptor engagement.

Mechanism of action

GHRP-6 engages two distinct receptor systems:

• GHS-R1a (ghrelin receptor). Activation drives Gαq-mediated calcium signalling in pituitary somatotrophs, producing GH release. GHS-R1a engagement in hypothalamic feeding circuits drives appetite stimulation.
• CD36 scavenger receptor. Distinct from GHS-R1a, CD36 is expressed on cardiomyocytes, endothelial cells, macrophages, and other tissues. GHRP-6 engagement of CD36 has been linked to its cardiovascular protection effects and to several of its non-GH-mediated activities — a feature that distinguishes the GHRP class from non-peptide GHS-R1a agonists like ibutamoren.

The dual receptor engagement complicates the pharmacology — GHRP-6's activities cannot be cleanly attributed to either GH release alone or to ghrelin-receptor signalling alone — but it also makes the molecule a useful research tool for studying ghrelin-receptor-independent effects of the GHRP class.

Preclinical research highlights

Cognitive effects and learning. Rodent studies have reported that GHRP-6 supports memory consolidation in spatial learning tasks, with effects that overlap with the broader role of ghrelin signalling in hippocampal plasticity. The cognitive effects of physical activity have been hypothesised to be mediated in part through endogenous GHRP-6/ghrelin-axis activity, with GH effects appearing secondary to direct GHS-R1a signalling.

Stroke and neuroprotection. Animal stroke models have reported that GHRP-6 administration shortly after ischaemic insult attenuates neuronal injury, reduces inflammation, and supports functional recovery — effects attributed to inhibition of apoptotic signalling and dampening of post-ischaemic inflammation in CNS tissue.

Parkinson's disease research. A 2018 line of investigation reported expression of GHS-R1a on substantia nigra neurons and reduced receptor density in patients with genetic Parkinson's risk. Rodent models in which GHS-R1a function is impaired have shown susceptibility to dopaminergic neurodegeneration, supporting interest in GHRP-6 and related agonists as research tools in Parkinson's-relevant models.

Wound healing and dermal effects. GHRP-6's CD36 engagement has been linked to pro-angiogenic activity in wound beds. Rat studies have reported accelerated wound closure, increased collagen and ECM protein deposition, and disruption of normal scarring patterns — observations that have supported research interest in dermatology and scar reduction contexts.

Cardiovascular protection. A particularly well-characterised body of GHRP-6 work involves cardiac ischaemia-reperfusion preparations. Studies in porcine and rodent models have reported reduced myocardial damage, improved left-ventricular function, reduced systemic vascular resistance, and attenuated oxidant cytotoxicity following GHRP-6 administration in models of acute myocardial infarction. The mechanism is attributed primarily to CD36 engagement rather than to GH release.

Behavioural and mood-related research. Studies in rodents have explored effects on sexual motivation, reward-seeking behaviour, and mood-related parameters under stress, with GHS-R1a-dependent modulation reported in selected brain regions.

Cachexia models. GHRP-6's appetite-stimulating activity has supported its evaluation in cachexia and wasting research, where its effects on protein synthesis (via GH-IGF-1) and on appetite combine.

Position in the GHRP family

Compared with related GHRPs:

• GHRP-2 (pralmorelin): More potent at GH release, less pronounced appetite effect
• Hexarelin: Strong cardiac effects with CD36 engagement, similar to GHRP-6
• Ipamorelin: Highly selective for GHS-R1a, with minimal CD36 engagement and minimal cortisol/prolactin effects
• MK-677 (ibutamoren): Non-peptide small molecule with oral bioavailability, no CD36 engagement

GHRP-6 occupies the middle of this family in terms of selectivity. Its CD36 engagement gives it a broader pharmacological profile than ipamorelin but introduces more pleiotropic effects than would be desired for studies seeking to isolate GH-axis activity.

Current research status

GHRP-6 remains an investigational research peptide. It has not been approved as a therapeutic by major regulatory authorities. It is listed by the World Anti-Doping Agency as a prohibited substance under category S2 (peptide hormones, growth factors, related substances and mimetics). Active research applications include:

• Cardiovascular protection mechanistic studies, particularly via CD36 engagement
• Ghrelin-axis biology and CNS plasticity research
• Wound healing and dermal repair models
• Cachexia and appetite-regulation models

Key takeaways for researchers

• GHRP-6 is a hexapeptide GHS-R1a agonist that also engages the scavenger receptor CD36.
• Dual receptor engagement explains its broader pharmacological profile relative to more selective GHRPs like ipamorelin.
• Reported preclinical effects span GH release, appetite stimulation, cardiac protection, neuroprotection, and wound healing.
• It is on the WADA Prohibited List and is not an approved therapeutic.

References

1. Bowers CY. History to the discovery of ghrelin. Methods in Enzymology. 2012;514:3–32.

---

This article is provided for educational and research purposes only. GHRP-6 is a research peptide. It is not an approved drug or therapeutic agent and is not intended for human consumption, diagnosis, treatment, cure, or prevention of any disease or condition. GHRP-6 is listed by the World Anti-Doping Agency as a prohibited substance. All work involving this peptide should be conducted by qualified personnel within an appropriate research setting and in compliance with applicable institutional and regulatory requirements.